This product is manufactured for researchers studying peptide chemistry, molecular interactions, analytical methodologies, formulation development, and other laboratory applications involving synthetic peptides
Here's why that combination is interesting: rapamycin inhibits mTOR, the cellular growth pathway that, when chronically overactivated, drives cellular senescence in follicle stem cell niches
The drugs would still not be FDA-approved, and the FDA would still not vouch for their safety or effectiveness. Koehl Robinson, founder and CEO of CeliaRX, a telehealth company that sells injectable and topical peptides compounded by a 503A pharmacy partner (not the ones on the FDAs potential unbanned list), says that if the peptides are reclassified, it would likely open up new possibilities for her customers, as well as lead to more clarity and less confusion

Technical Specifications Compound: Glycyl-L-Histidyl-L-Lysine Copper Complex (GHK-Cu) Format: Lyophilized peptide powder Strength: 50 mg per vial Purity: 9899% (COA included) Appearance: Blue-tinted lyophilized powder Category: Research peptide reagent Intended Use This product is intended solely for: Laboratory experimentation Controlled in-vitro research Molecular and biochemical pathway studies Metal-peptide interaction research Non-human preclinical modeling Academic and institutional scientific projects Not intended for: Human or animal consumption Injection, ingestion, inhalation, topical, or cosmetic use Medical, therapeutic, or dermatological applications This material is not approved by Health Canada, FDA, or any regulatory body for clinical or cosmetic use